Flight Mechanics/Estimation Theory Symposium 1995

This conference publication includes 41 papers and abstracts presented at the Flight Mechanics/ Estimation Theory Symposium on May 16-18, 1995. Sponsored by the Flight Dynamics Division of Goddard Space Flight Center, this symposium featured technical papers on a wide range of issues related to orbit-attitude prediction, determination, and control; attitude sensor calibration; attitude determination error analysis; attitude dynamics; and orbit decay and maneuver strategy. Government, industry, and the academic community participated in the preparation and presentation of these papers

Flight Mechanics/Estimation Theory Symposium, 1994

This conference publication includes 41 papers and abstracts presented at the Flight Mechanics/Estimation Theory Symposium on May 17-19, 1994. Sponsored by the Flight Dynamics Division of Goddard Space Flight Center, this symposium featured technical papers on a wide range of issues related to orbit-attitude prediction, determination and control; attitude sensor calibration; attitude determination error analysis; attitude dynamics; and orbit decay and maneuver strategy. Government, industry, and the academic community participated in the preparation and presentation of these papers

Geostationary Coastal and Air Pollution Events (GEO CAPE) Instrument Performance Study

The Ultimate objective of the GEO-CAPE 2014 study: Quantify the cost impact of very specific changes in instrument performance! The customer has defined 4 instrument types they are notionally interested in:! FR: Filter Radiometer! WAS: Wide Angle Spectrometer! MSS: Multi Slit Spectrometer! SSS: Single Slit Spectrometer

Operational considerations of using GPS for spacecraft navigation

The Flight Dynamics Facility (FDF) at the NASA Goddard Space Flight Center (GSFC) has provided operational spacecraft orbit support for many years, currently generating orbit products for about 20 satellites. To date, operational orbit determination in the FDF has been performed on the ground using data from ground-based or space-based tracking systems. Current development of spaceborne Global Positioning System (GPS) receivers is projected to have a significant effect on the support needed for operational satellite navigation. This paper identifies the functions performed in spacecraft navigation and examines and quantifies how the functions and support levels will be affected as onboard GPS receivers are implemented on spacecraft. Cases are considered spacecraft using or not using NASA ground and space networks resources

CfA4: Light Curves for 94 Type Ia Supernovae

We present multi-band optical photometry of 94 spectroscopically-confirmed Type Ia supernovae (SN Ia) in the redshift range 0.0055 to 0.073, obtained between 2006 and 2011. There are a total of 5522 light curve points. We show that our natural system SN photometry has a precision of roughly 0.03 mag or better in BVr'i', 0.06 mag in u', and 0.07 mag in U for points brighter than 17.5 mag and estimate that it has a systematic uncertainty of 0.014, 0.010, 0.012, 0.014, 0.046, and 0.073 mag in BVr'i'u'U, respectively. Comparisons of our standard system photometry with published SN Ia light curves and comparison stars reveal mean agreement across samples in the range of ~0.00-0.03 mag. We discuss the recent measurements of our telescope-plus-detector throughput by direct monochromatic illumination by Cramer et al (in prep.). This technique measures the whole optical path through the telescope, auxiliary optics, filters, and detector under the same conditions used to make SN measurements. Extremely well-characterized natural-system passbands (both in wavelength and over time) are crucial for the next generation of SN Ia photometry to reach the 0.01 mag accuracy level. The current sample of low-z SN Ia is now sufficiently large to remove most of the statistical sampling error from the dark energy error budget. But pursuing the dark-energy systematic errors by determining highly-accurate detector passbands, combining optical and near-infrared (NIR) photometry and spectra, using the nearby sample to illuminate the population properties of SN Ia, and measuring the local departures from the Hubble flow will benefit from larger, carefully measured nearby samples.Comment: 43 page

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.

Global dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G are suggestive of a selective advantage but may also be due to a random founder effect. We investigate the hypothesis for positive selection of spike D614G in the United Kingdom using more than 25,000 whole genome SARS-CoV-2 sequences. Despite the availability of a large dataset, well represented by both spike 614 variants, not all approaches showed a conclusive signal of positive selection. Population genetic analysis indicates that 614G increases in frequency relative to 614D in a manner consistent with a selective advantage. We do not find any indication that patients infected with the spike 614G variant have higher COVID-19 mortality or clinical severity, but 614G is associated with higher viral load and younger age of patients. Significant differences in growth and size of 614G phylogenetic clusters indicate a need for continued study of this variant

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years